Last reviewed · How we verify
NCT06119022
CT Myocardial Perfusion to Guide the Diagnosis and Treatment of Patients With Stable Coronary Artery Disease (POTENTIAL)
NA trial testing Invasive coronary angiography in Treatment Decision, Coronary Artery Disease in 660 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 660 |
| Start date | 30 September 2023 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2025 |
| Sites | 4 locations across China |
Drugs / interventions tested
- Invasive coronary angiography
- routine medical treatment
Conditions studied
- Treatment Decision, Coronary Artery Disease — all drugs for Treatment Decision, Coronary Artery Disease →
Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Who can join
Adults 18 to 80, any sex, with Treatment Decision, Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall goal of this project is to compare the non-revascularization rate of coronary angiography in patients with stable coronary artery disease (CAD) within 90 days after CT myocardial perfusion imaging (CT-MPI) or Single-Photon Emission Computed Tomography myocardial perfusion imaging (SPECT-MPI), and 1-year major adverse cardiovascular events (MACE).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06119022
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Invasive coronary angiography
Trials testing the same drug.
- NCT06559332 — Coronary Artery Disease Assessment Strategies in TAVI Patients · NA · recruiting
- NCT05799092 — Invasive Versus Non-invasive Approach in Symptomatic Patient With Non-High Risk Coronary Artery Stenosis · NA · recruiting
- NCT06543641 — Evaluation of Long Coronary Artery Stents With Third-generation Dual-source Computed Tomography Angiography · NA · completed
- NCT05419583 — Targeting Investigation and Treatment in Patients With Type 2 Myocardial Infarction · NA · completed
- NCT06311071 — The Predictive Value of Coronary Artery Calcium Score · completed
Other Chinese Academy of Medical Sciences, Fuwai Hospital trials
Trials by the same sponsor.
- NCT07450196 — A Prospective, Multicenter, Observational Study Evaluating Safety and Effectiveness of SAPIEN 3 Transcatheter Aortic Val · not yet recruiting
- NCT07511309 — FFR-Guided Revascularization in Atherosclerotic Renal Artery Stenosis: A Randomized Controlled Trial · NA · not yet recruiting
- NCT07054541 — A Novel Echocardiography-Guided Strategy for Percutateous Closure of Atrial Septal Defect Assisted by PannaWire · Phase 4 · not yet recruiting
- NCT07458672 — TAVR for Aortic Regurgitation Under TTE Guidance · NA · not yet recruiting
- NCT07462325 — Proteomic and Inflammatory Omics Changes With Colchicine Therapy in Coronary Heart Disease · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06119022 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences, Fuwai Hospital
- Last refreshed: 7 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06119022.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing